Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2008 4
2009 4
2010 4
2011 6
2012 8
2013 8
2014 12
2015 10
2016 11
2017 15
2018 9
2019 14
2020 12
2021 13
2022 13
2023 17
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake.
Williamson A, Norris DM, Yin X, Broadaway KA, Moxley AH, Vadlamudi S, Wilson EP, Jackson AU, Ahuja V, Andersen MK, Arzumanyan Z, Bonnycastle LL, Bornstein SR, Bretschneider MP, Buchanan TA, Chang YC, Chuang LM, Chung RH, Clausen TD, Damm P, Delgado GE, de Mello VD, Dupuis J, Dwivedi OP, Erdos MR, Fernandes Silva L, Frayling TM, Gieger C, Goodarzi MO, Guo X, Gustafsson S, Hakaste L, Hammar U, Hatem G, Herrmann S, Højlund K, Horn K, Hsueh WA, Hung YJ, Hwu CM, Jonsson A, Kårhus LL, Kleber ME, Kovacs P, Lakka TA, Lauzon M, Lee IT, Lindgren CM, Lindström J, Linneberg A, Liu CT, Luan J, Aly DM, Mathiesen E, Moissl AP, Morris AP, Narisu N, Perakakis N, Peters A, Prasad RB, Rodionov RN, Roll K, Rundsten CF, Sarnowski C, Savonen K, Scholz M, Sharma S, Stinson SE, Suleman S, Tan J, Taylor KD, Uusitupa M, Vistisen D, Witte DR, Walther R, Wu P, Xiang AH, Zethelius B; Meta-Analysis of Glucose and Insulin-related Traits Consortium (MAGIC); Ahlqvist E, Bergman RN, Chen YI, Collins FS, Fall T, Florez JC, Fritsche A, Grallert H, Groop L, Hansen T, Koistinen HA, Komulainen P, Laakso M, Lind L, Loeffler M, März W, Meigs JB, Raffel LJ, Rauramaa R, Rotter JI, Schwarz PEH, Stumvoll M, Sundström … See abstract for full author list ➔ Williamson A, et al. Among authors: vistisen d. Nat Genet. 2023 Jun;55(6):973-983. doi: 10.1038/s41588-023-01408-9. Epub 2023 Jun 8. Nat Genet. 2023. PMID: 37291194 Free PMC article.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: vistisen d. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Low birthweight is associated with a higher incidence of type 2 diabetes over two decades independent of adult BMI and genetic predisposition.
Wibaek R, Andersen GS, Linneberg A, Hansen T, Grarup N, Thuesen ACB, Jensen RT, Wells JCK, Pilgaard KA, Brøns C, Vistisen D, Vaag AA. Wibaek R, et al. Among authors: vistisen d. Diabetologia. 2023 Sep;66(9):1669-1679. doi: 10.1007/s00125-023-05937-0. Epub 2023 Jun 12. Diabetologia. 2023. PMID: 37303008 Free PMC article.
Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
Stougaard EB, Rossing P, Vistisen D, Banks P, Girard M, Davies MJ, Persson F. Stougaard EB, et al. Among authors: vistisen d. Diabetes Obes Metab. 2023 Jul;25(7):1874-1882. doi: 10.1111/dom.15047. Epub 2023 Mar 20. Diabetes Obes Metab. 2023. PMID: 36872068 Clinical Trial.
138 results